Emergent BioSolutions Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Emergent BioSolutions Inc. on August 24, 2011. The report details a material definitive agreement entered into by Emergent BioDefense Operations Lansing Inc., a wholly-owned subsidiary of the Company.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The reported event is a contract modification with no financial cost.
Material Changes
On August 24, 2011, the Company's subsidiary entered into a no-cost modification of a contract dated September 25, 2007, with the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services. The modification includes:
- Extension of the period of performance from September 1, 2011, to October 31, 2011.
- Extension of the delivery date for certain milestone deliverables related to a post-exposure prophylaxis (PEP) indication for BioThrax® to October 31, 2011.
- No additional cost to the Company.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future outlook, or discussion of new risks or contingencies beyond the specific contract extension. The unusual item noted is the extension of delivery timelines for regulatory milestones without financial penalty.
Key Facts for Investor Verification
- Verify the impact of the delayed BioThrax® PEP milestone delivery on future revenue recognition.
- Confirm the status of the underlying September 2007 BARDA contract and any other pending deliverables.
- Review subsequent filings to determine if the October 31, 2011, deadline was met or if further extensions were required.